Work

A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2‐Positive Breast Cancer Cells

Year: 2015

Type: article

Abstract: We report a rationally designed nanobody activation immunotherapeutic that selectively redirects anti-dinitrophenyl (anti-DNP) antibodies to the surface of HER2-positive breast cancer cells, resulting in their targeted destruction by antibody-dependent cellular cytotoxicity. As nanobodies are relatively easy to express, stable, can be humanized, and can be evolved to potently and selectively bind virtually any disease-relevant cell surface receptor, we anticipate broad utility of this therapeutic strategy.

Source: ChemBioChem

DOI: 10.1002/cbic.201500591

Authors: Melissa A. Gray, Ran N. Tao, Sandra M. DePorter, David A. Spiegel, Brian R. McNaughton

Institutions: Colorado State University, Yale University

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Colorado State University, National Institute of General Medical Sciences, National Institute of Biomedical Imaging and Bioengineering